Comparative nephrotoxicity of carboplatin and cisplatin in combination with tobramycin

Bregman, Carla L.; Williams, Patricia D.

doi:10.1007/bf00262279

Cited by 20 publications

(5 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study using conventional doses of carboplatin we have found no overall evidence of a similar, early reduction in GFR, patients being as likely to experience an improvement in their GFR as they are a decline in the period of up to 1 month carboplatin ( Figure 1, Table I). Carboplatin has been shown to be nephrotoxic in rats, but only in combination with the aminoglycoside tobramycin, and not when used alone (Bregman & Williams, 1986). We have found no overall evidence of significant nephrotoxicity in patients with metastatic germ cell tumours at any time after treatment with carboplatin.…”

Section: Discussioncontrasting

confidence: 50%

The effect of carboplatin on renal function in patients with metastatic germ cell tumours

Mason

Nicholls²,

Horwich³

1991

Br J Cancer

View full text Add to dashboard Cite

Summary Renal function was determined before and at varying times after chemotherapy in 62 patients with metastatic germ cell tumours treated with carboplatin. Eighteen patients were excluded because of urinary tract obstruction, leaving 44 evaluable patients treated with carboplatin either as a single agent (13 patients) or in combination with other agents (31 patients). No significant differences were observed in mean"Cr-labelled Ethylenediamine tetraacetic acid (EDTA) clearances before and after carboplatin in either the group as a whole (P = 0.58), or when assessment at 1 month or less (P = 0.4), 3 months or less (P = 0.91), or later than 3 months (P = 0.38) were analysed. Carboplatin does not have significant renal toxicity when used at conventional dosage in patients with germ cell tumours.

show abstract

Section: Discussioncontrasting

confidence: 50%

The effect of carboplatin on renal function in patients with metastatic germ cell tumours

Mason

Nicholls²,

Horwich³

1991

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…Necrotic cell death was observed when a high concentration of cisplatin (millimolar) was used, while lower concentrations of cisplatin (micromolar) led to apoptosis [23]. In experimental models and in patients, carboplatin treatment rarely results in nephrotoxicity [11, 24, 25]. Nephrotoxicity has not been reported in any of the oxaliplatin trials, allowing administration of oxaliplatin without hydration [26].…”

Section: Cisplatin Toxicitiesmentioning

confidence: 99%

Membrane Transporters as Mediators of Cisplatin Effects and Side Effects

2012

View full text Add to dashboard Cite

Transporters are important mediators of specific cellular uptake and thus, not only for effects, but also for side effects, metabolism, and excretion of many drugs such as cisplatin. Cisplatin is a potent cytostatic drug, whose use is limited by its severe acute and chronic nephro-, oto-, and peripheral neurotoxicity. For this reason, other platinum derivatives, such as carboplatin and oxaliplatin, with less toxicity but still with antitumoral action have been developed. Several transporters, which are expressed on the cell membranes, have been associated with cisplatin transport across the plasma membrane and across the cell: the copper transporter 1 (Ctr1), the copper transporter 2 (Ctr2), the P-type copper-transporting ATPases ATP7A and ATP7B, the organic cation transporter 2 (OCT2), and the multidrug extrusion transporter 1 (MATE1). Some of these transporters are also able to accept other platinum derivatives as substrate. Since membrane transporters display a specific tissue distribution, they can be important molecules that mediate the entry of platinum derivatives in target and also nontarget cells possibly mediating specific effects and side effects of the chemotherapeutic drug. This paper summarizes the literature on toxicities of cisplatin compared to that of carboplatin and oxaliplatin and the interaction of these platinum derivatives with membrane transporters.

show abstract

“…Because hOCT2 participates in the process of creatinine secretion into the urine, and because cisplatin is also a substrate of this transporter, the measurement of serum creatinine as a marker of renal function in patients treated with cisplatin can be misleading . Treatment with carboplatin or oxaliplatin rarely results in nephrotoxicity. Figure summarizes the transporters involved in renal handling of cisplatin and oxaliplatin.…”

Section: Chemotherapeutic Drugs That Interact With Transporters For Omentioning

confidence: 99%

“…creatinine as a marker of renal function in patients treated with cisplatin can be misleading. 70 Treatment with carboplatin 53,71,72 or oxaliplatin 73 rarely results in nephrotoxicity. Figure 1 summarizes the transporters involved in renal handling of cisplatin and oxaliplatin.…”

Section: Platinum Derivativesmentioning

confidence: 99%

The Role of Transporters in the Toxicity of Chemotherapeutic Drugs: Focus on Transporters for Organic Cations

Hucke

Ciarimboli

2016

The Journal of Clinical Pharma

View full text Add to dashboard Cite

The introduction of chemotherapy in the treatment of cancer is one of the most important achievements of modern medicine, even allowing the cure of some lethal diseases such as testicular cancer and other malignant neoplasms. The number and type of chemotherapeutic agents available have steadily increased and have developed until the introduction of targeted tumor therapy. It is now evident that transporters play an important role for determining toxicity of chemotherapeutic drugs not only against target but also against nontarget cells. This is of special importance for intracellularly active hydrophilic drugs, which cannot freely penetrate the plasma membrane. Because many important chemotherapeutic agents are substrates of transporters for organic cations, this review discusses the known interaction of these substances with these transporters. A particular focus is given to the role of transporters for organic cations in the development of side effects of chemotherapy with platinum derivatives and in the efficacy of recently developed tyrosine kinase inhibitors to specifically target cancer cells. It is evident that specific inhibition of uptake transporters may be a possible strategy to protect against undesired side effects of platinum derivatives without compromising their antitumor efficacy. These transporters are also important for efficient targeting of tyrosine kinase inhibitors to cancer cells. However, in order to achieve the aims of protecting from undesired toxicities and improving the specificity of uptake by tumor cells, an exact knowledge of transporter expression, function, regulation under normal and pathologic conditions, and of genetically and epigenetically regulation is mandatory.

show abstract

Comparative nephrotoxicity of carboplatin and cisplatin in combination with tobramycin

Cited by 20 publications

References 19 publications

The effect of carboplatin on renal function in patients with metastatic germ cell tumours

The effect of carboplatin on renal function in patients with metastatic germ cell tumours

Membrane Transporters as Mediators of Cisplatin Effects and Side Effects

The Role of Transporters in the Toxicity of Chemotherapeutic Drugs: Focus on Transporters for Organic Cations

Contact Info

Product

Resources

About